Physician profile
David K Winchell
NPI 1871550921
$15,280.18
in general payments reported to CMS, 2019-2025
29 companies · $2,947 in 2025
The $2,947 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,613 · 2022: $2,731 · 2023: $3,188 · 2024: $3,800 · 2025: $2,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,670 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,669.73 |
| Education | $265.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,139.43 | 2021-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,995.86 | 2021-2025 | |
| Amgen INC. | $1,325.97 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $975.07 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Novartis Pharmaceuticals Corporation | $959.58 | 2021-2025 | |
| Genzyme Corporation | $923.87 | 2021-2025 | |
| Dermavant Sciences, INC. | $923.30 | 2022-2024 | Vtama |
| Lilly USA, LLC | $904.33 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $850.10 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $657.85 | 2021-2025 | Winlevi |
| Pfizer INC. | $603.43 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $549.96 | 2023-2025 | Zoryve |
| Ucb, INC. | $418.46 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $417.18 | 2021-2022 | |
| Incyte Corporation | $282.59 | 2021-2025 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $258.76 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $197.81 | 2022-2025 | Dupixent |
| Organon LLC | $193.04 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.54 | 2024-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135.47 | 2021-2024 | Siliq, Cabtreo |
| Epi Health, LLC | $109.45 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $92.58 | 2023-2025 | |
| Almirall LLC | $74.10 | 2021-2025 | Klisyri |
| Regeneron Pharmaceuticals, INC. | $33.99 | 2025 | Dupixent |
| Sandoz INC. | $20.83 | 2021 | |
| Sanofi US Services INC. | $19.57 | 2025 | |
| Biofrontera INC. | $19.25 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Genentech USA, INC. | $17.47 | 2021 | |
| Fresenius Kabi USA, LLC | $17.34 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Winchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.